Podcast Episodes
Back to Search
263: Biogen's messy board, Laronde's data problem, & the downside of a boom
Our colleague Allison DeAngelis joins us to share her reporting on how the handsomely funded Laronde Therapeutics, billed as “Moderna 2.0,” ran into …
3 years, 4 months ago
262: Merck v. USA, the best of ASCO, and Leqembi at the FDA
STAT Washington correspondent Rachel Cohrs joins us to explain Merck's lawsuit against the federal government and why the company believes drug prici…
3 years, 4 months ago
261: Fake medical devices, real cancer drugs, & curious Ozempic effects
Our colleague Lizzy Lawrence joins us to explain the shocking story of a medical device company that sold fake implants and the warped system that ma…
3 years, 4 months ago
260: ChatGPT in medicine, a boom in weight loss pills, & Sarepta at the FDA
As hospitals and health care companies are racing to implement large language models like ChatGPT into their businesses, STAT reporter Casey Ross joi…
3 years, 5 months ago
259: The FTC v. Amgen, Sarepta's future, & Galapagos' turnaround
Jared Holz, biotech strategist at Mizuho Securities, joins us to explain why federal regulators are suing to block Amgen's $28 billion merger with Ho…
3 years, 5 months ago
258: Pharma vs. PBMs, Sarepta at the FDA, & a bold idea gone awry
We discuss a Senate hearing that put major pharma CEOs in the same room with the middlemen they love to blame for rising drug prices, with mixed resu…
3 years, 5 months ago
257: Lilly's Alzheimer's success, a milestone FDA approval, & Moderna's shrinking business
Eli Lilly’s investigational medicine for Alzheimer’s met its goals in an all-important clinical trial, and we explain the results, their implications…
3 years, 5 months ago
256: Explaining the E.U.'s pharma overhaul, Lilly's booming business, & a long-awaited drug approval
Andrew Joseph, STAT's Europe correspondent, joins us to explain the EU's sweeping proposal to overhaul how new drugs are regulated on the continent —…
3 years, 6 months ago
255: Sarepta's pivotal moment, biotech's big week, & the future of Covid boosters
Our colleague Helen Branswell joins us to explain the latest news on Covid-19 boosters and the implications of a Marburg outbreak in Equatorial Guine…
3 years, 6 months ago
254: The legal battle over abortion, an FDA 'bully pulpit' and Moderna's future
Jeremy Levin, CEO of Ovid Therapeutics, joins us to discuss a judge’s decision to overturn the FDA approval of an abortion pill and why he believes i…
3 years, 6 months ago